Recommended Readings
Download the consensus statement in English [PDF]
Katherine Cheung, Caleigh Propes, Edward Jacobs, Brian D. Earp, David B. Yaden (February 2025) Response to the US Congress Request for Information (RFI) on psychedelic research for mental health, as submitted by the Hub at Oxford for Psychedelic Ethics Download the paper in English [PDF]
Appelbaum, P. S. (2022). Psychedelic research and the real world. Nature, 609(7929), S95-S95.
Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022). Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. Journal of Psychopharmacology, 36(10), 1100-1117.
Celidwen, Y., Redvers, N., Githaiga, C., Calambás, J., Añaños, K., Chindoy, M. E., … & Sacbajá, A. (2023). Ethical principles of traditional indigenous medicine to guide western psychedelic research and practice. The Lancet Regional Health–Americas, 18.
Cheung, K., Patch, K., Earp, B. D., & Yaden, D. B. (2023). Psychedelics, meaningfulness, and the “proper scope” of medicine: continuing the conversation. Cambridge Quarterly of Healthcare Ethics, 1-7.
Devenot, N., Tumilty, E., Buisson, M., McNamee, S., Nickles, D., & Ross, L. K. (2022). A Precautionary Approach to Touch in Psychedelic-Assisted Therapy. Bill of Health.
Earp and Savulescu (2021). Love Drugs: The Chemical Future of Relationships. Stanford, CA: Redwood Press.
Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R., … & Prideaux, E. (2023). Extended difficulties following the use of psychedelic drugs: A mixed methods study. PLOS ONE, 18(10), e0293349.
Fogg, C., Michaels, T. I., de la Salle, S., Jahn, Z. W., & Williams, M. T. (2021). Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies. Experimental and Clinical Psychopharmacology, 29(5), 539.
Jacobs, E., Murphy-Beiner, A., Rouiller, I., Nutt, D., & Spriggs, M. J. (2024). When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research. Neuroethics, 17(1), 3.
Jacobs, E., Yaden, D. B., & Earp, B. D. (2023). Toward a Broader Psychedelic Bioethics. AJOB neuroscience, 14(2), 126-129.
McGuire et al. (under review). Developing an Ethics and Policy Framework for Psychedelic Clinical Care
McGuire, A. L., Lynch, H. F., Grossman, L. A., & Cohen, I. G. (2023). Pressing regulatory challenges for psychedelic medicine. Science, 380(6643), 347-350.
McMillan, R. M. (2022). Psychedelic injustice: should bioethics tune in to the voices of psychedelic-using communities?. Medical Humanities, 48(3), 269-272.
Neitzke-Spruill, L. (2020). Race as a component of set and setting: How experiences of race can influence psychedelic experiences. Journal of Psychedelic Studies, 4(1), 51-60.
Noorani, T. (2021). Containment matters: Set and setting in contemporary psychedelic psychiatry. Philosophy, Psychiatry, & Psychology, 28(3), 201-216.
Ortiz, C. E., Dourron, H. M., Sweat, N. W., Garcia-Romeu, A., MacCarthy, S., Anderson, B. T., & Hendricks, P. S. (2022). Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. Neuropharmacology, 214, 109127.;
Thrul, J., & Garcia-Romeu, A. (2021). Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment. Drugs: Education, Prevention and Policy, 28(3), 211-214.
Yaden, D. B., Potash, J. B., & Griffiths, R. R. (2022). Preparing for the bursting of the psychedelic hype bubble. JAMA psychiatry, 79(10), 943-944.
Yaden, D. B., Earp, B. D., & Griffiths, R. R. (2022). Ethical issues regarding nonsubjective psychedelics as standard of care. Cambridge Quarterly of Healthcare Ethics, 31(4), 464-471.